Votrient
Generic Name
Pazopanib 200 mg tablet
Manufacturer
Novartis Pharmaceuticals Corporation
Country
Switzerland
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| votrient 200 mg tablet | ৳ 388.10 | ৳ 11,643.00 |
Description
Overview of the medicine
Votrient (pazopanib) is an oral multi-targeted receptor tyrosine kinase inhibitor used for the treatment of advanced renal cell carcinoma (RCC) and advanced soft tissue sarcoma (STS) in patients who have received prior chemotherapy.
Uses & Indications
Dosage
Adults
800 mg once daily, taken at least one hour before or two hours after a meal. Doses of 200 mg, 400 mg, or 600 mg may be used for dose modifications based on tolerability.
Elderly
No specific dose adjustment required based on age.
Renal_impairment
No dose adjustment required for mild to moderate renal impairment. Data limited for severe renal impairment, use with caution.
How to Take
Oral administration. Tablets should be swallowed whole with water, not crushed or chewed. Take at least one hour before or two hours after a meal.
Mechanism of Action
Pazopanib inhibits multiple tyrosine kinases involved in tumor growth, angiogenesis, and metastasis. These include VEGFR-1, -2, -3, PDGFR-α, -β, c-Kit, and FGFR-1, -3.
Pharmacokinetics
Onset
Clinical onset of action can be observed within weeks; however, it varies by indication and individual response.
Excretion
Mainly via feces (>80%), with <4% excreted in urine.
Half life
Approximately 30.6 hours (range: 21-50 hours).
Absorption
Slow absorption, peak plasma concentrations typically occur 2-4 hours post-dose. Bioavailability is variable and increased with food.
Metabolism
Primarily hepatic, predominantly by CYP3A4, with minor contributions from CYP1A2 and CYP2C8.
Side Effects
Contraindications
- Hypersensitivity to pazopanib or any component of the formulation.
- Severe hepatic impairment (Child-Pugh Class C).
Drug Interactions
Strong CYP3A4 inducers (e.g., rifampin, phenytoin)
Decrease pazopanib exposure; avoid co-administration.
Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin)
Increase pazopanib exposure; avoid co-administration or reduce pazopanib dose.
Drugs that prolong QT interval (e.g., antiarrhythmics, antipsychotics)
Increased risk of QT prolongation; use with caution.
Gastric pH-elevating agents (e.g., proton pump inhibitors, H2-receptor antagonists, antacids)
Decrease pazopanib absorption; avoid or separate administration.
Storage
Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Keep out of reach of children.
Overdose
No specific antidote for pazopanib overdose. Management should involve supportive care and monitoring for adverse reactions. Monitor liver function, blood pressure, and ECG.
Pregnancy & Lactation
Pregnancy: May cause fetal harm. Advise pregnant women of the potential risk to the fetus. Lactation: Unknown if excreted in human milk; advise women not to breastfeed during treatment and for 2 weeks after the last dose.
Side Effects
Contraindications
- Hypersensitivity to pazopanib or any component of the formulation.
- Severe hepatic impairment (Child-Pugh Class C).
Drug Interactions
Strong CYP3A4 inducers (e.g., rifampin, phenytoin)
Decrease pazopanib exposure; avoid co-administration.
Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin)
Increase pazopanib exposure; avoid co-administration or reduce pazopanib dose.
Drugs that prolong QT interval (e.g., antiarrhythmics, antipsychotics)
Increased risk of QT prolongation; use with caution.
Gastric pH-elevating agents (e.g., proton pump inhibitors, H2-receptor antagonists, antacids)
Decrease pazopanib absorption; avoid or separate administration.
Storage
Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Keep out of reach of children.
Overdose
No specific antidote for pazopanib overdose. Management should involve supportive care and monitoring for adverse reactions. Monitor liver function, blood pressure, and ECG.
Pregnancy & Lactation
Pregnancy: May cause fetal harm. Advise pregnant women of the potential risk to the fetus. Lactation: Unknown if excreted in human milk; advise women not to breastfeed during treatment and for 2 weeks after the last dose.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Typically 24-36 months from manufacturing date, check product label for specific expiry.
Availability
Pharmacies, hospitals, specialized oncology centers
Approval Status
FDA Approved
Patent Status
Patent expired for generic versions to be available, but brand still protected in some regions.
Clinical Trials
Pazopanib was approved based on randomized, double-blind, placebo-controlled trials such as VEG105192 for RCC and VEG110727 for STS, demonstrating significant improvements in progression-free survival.
Lab Monitoring
- Liver function tests (ALT, AST, bilirubin) at baseline and regularly during treatment.
- Blood pressure monitoring.
- Thyroid function tests.
- Urinalysis for proteinuria.
- ECG for QT prolongation.
- Complete blood count.
Doctor Notes
- Monitor liver function closely, especially during the first few weeks of treatment.
- Manage hypertension aggressively to prevent complications.
- Educate patients on potential side effects and when to seek medical attention.
Patient Guidelines
- Take Votrient exactly as prescribed by your doctor.
- Do not crush, chew, or split the tablets.
- Take the medication on an empty stomach (at least 1 hour before or 2 hours after a meal).
- Report any severe side effects immediately to your doctor, especially liver problems, heart problems, or unusual bleeding.
Missed Dose Advice
If a dose is missed, do not take it if it is less than 12 hours until the next scheduled dose. Resume treatment with the next scheduled dose. Do not take two doses to make up for a missed dose.
Driving Precautions
May cause fatigue, dizziness, or vision disturbances. Patients should exercise caution when driving or operating machinery until they are reasonably certain that pazopanib does not adversely affect their ability to perform such activities.
Lifestyle Advice
- Maintain good hydration.
- Avoid grapefruit products.
- Avoid driving or operating machinery if you experience dizziness or fatigue.
- Regularly monitor blood pressure at home if advised by your doctor.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.